ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Menarini Group and Laboratorios Silanes S.A. de C.V. side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Menarini GroupLaboratorios Silanes S.A. de C.V.
studies on the registry8156
open to participants now141
phase 3 studies under way21
reach primary completion within a year71
programswith a study of their own in two years78

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMenarini GroupLaboratorios Silanes S.A. de C.V.
Phase 1

Menarini Group: 4 of its 7 programs at phase 1

  1. Tamsulosinphase 1
  2. KIF18A Inhibitor MEN2501phase 1
  3. Torsemidephase 1
  4. Ibuprofenphase 1
57%

Laboratorios Silanes S.A. de C.V.: 2 of its 8 programs at phase 1

  1. A1: Etoricoxib / Betamethasone in fixed dose combination tablet. (Laboratorios Silanes S.A. de C.V.)phase 1
  2. Aspirinphase 1
25%
Phase 2

Menarini Group: 2 of its 7 programs at phase 2

  1. KAT6 Inhibitor MEN2312phase 2
  2. RPX7009phase 2
29%
00%
Phase 3

Menarini Group: 1 of its 7 programs at phase 3

  1. elacestrantphase 3
14%

Laboratorios Silanes S.A. de C.V.: 6 of its 8 programs at phase 3

  1. Etoricoxibphase 3
  2. Acetaminophenphase 3
  3. Celecoxibphase 3
  4. dexketoprofenphase 3
  5. Betamethasonephase 3

and 1 more — sign in to see them all

75%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Menarini Group3 readouts · 0 phase 3

Menarini Group, Nov ’26: 1 program whose next study reaches primary completion

  1. elacestrantphase 3 · Nov 0 · NCT05596409
··········

Menarini Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. RPX7009phase 2 · Oct 0 · NCT06828848
  2. KAT6 Inhibitor MEN2312phase 2 · Oct 24 · NCT06638307
Laboratorios Silanes S.A. de C.V.1 readouts · 1 phase 3·

Laboratorios Silanes S.A. de C.V., Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Etoricoxibphase 3 · Dec 31 · NCT06863701
··········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Menarini Group

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Laboratorios Silanes S.A. de C.V.

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionMenarini GroupLaboratorios Silanes S.A. de C.V.
Painboth · compare here

Menarini Group in Pain: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Pain in search

Laboratorios Silanes S.A. de C.V. in Pain: 3 programs

  1. Etoricoxibphase 3
  2. Acetaminophenphase 3
  3. dexketoprofenphase 3

Their studies: Laboratorios Silanes S.A. de C.V.’s studies of Pain in search

Osteoarthritisboth · compare here

Menarini Group in Osteoarthritis: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Osteoarthritis in search

Laboratorios Silanes S.A. de C.V. in Osteoarthritis: 2 programs

  1. Etoricoxibphase 3
  2. Celecoxibphase 3

Their studies: Laboratorios Silanes S.A. de C.V.’s studies of Osteoarthritis in search

Pain, Postoperativeboth · compare here

Menarini Group in Pain, Postoperative: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Pain, Postoperative in search

Laboratorios Silanes S.A. de C.V. in Pain, Postoperative: 2 programs

  1. Acetaminophenphase 3
  2. Celecoxibphase 3

Their studies: Laboratorios Silanes S.A. de C.V.’s studies of Pain, Postoperative in search

Feverboth · compare here

Menarini Group in Fever: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Fever in search

Laboratorios Silanes S.A. de C.V. in Fever: 1 program

  1. Acetaminophenphase 3

Their studies: Laboratorios Silanes S.A. de C.V.’s studies of Fever in search

Osteoarthritis, Kneeboth · compare here

Menarini Group in Osteoarthritis, Knee: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Osteoarthritis, Knee in search

Laboratorios Silanes S.A. de C.V. in Osteoarthritis, Knee: 1 program

  1. Celecoxibphase 3

Their studies: Laboratorios Silanes S.A. de C.V.’s studies of Osteoarthritis, Knee in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetMenarini GroupLaboratorios Silanes S.A. de C.V.
PTGS2IbuprofenruleAcetaminophenrule, Celecoxibrule, dexketoprofenrule, Etoricoxibrule, Aspirinrule
PTGS1IbuprofenruleAcetaminophenrule, dexketoprofenrule, Aspirinrule
A target, or a pathogen for a vaccine, known for: Menarini Group 6 of 7 · Laboratorios Silanes S.A. de C.V. 7 of 8 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.